Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)
NCT06255210
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
25
Enrollment
OTHER
Sponsor class
Conditions
Olfactory Neuroblastoma
Interventions
DRUG:
Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP)
Sponsor
Hongmeng Yu